Publications by authors named "Malcolm Gottesman"

Claim this Profile
D
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Dejan Jakimovski, Katelyn S Kavak, Patricia K Coyle, Andrew D Goodman, Malcolm Gottesman

J Neurol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
Dejan Jakimovski, Katelyn S Kavak, Karen Zakalik, Corey McGraw, Malcolm Gottesman

J Neurol Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC).
Dejan Jakimovski, Katelyn S Kavak, Karen Zakalik, Timothy Coetzee, Malcolm Gottesman

Mult Scler· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Dejan Jakimovski, Katelyn S Kavak, Caila B Vaughn, Andrew D Goodman, Patricia K Coyle, Malcolm Gottesman

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center.
Erica Parrotta, Ilya Kister, Leigh Charvet, Carrie Sammarco, Valerie Saha, Malcolm Gottesman

Neurol Neuroimmunol Neuroinflamm· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate.
Stephen Farley, Malcolm H Gottesman, Sharon Friedman-Urevich, Janin Ye, Mark Shen

Surg Neurol Int· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).
Robert Zivadinov, Diane L Cookfair, Lauren Krupp, Aaron E Miller, Neil Lava, Malcolm Gottesman

BMC Neurol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Few patients with neurodegenerative disorders require spinal surgery.
Nancy E Epstein, Malcolm Gottesman

Surg Neurol Int· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An approach to natalizumab hypersensitivity: a case series of induction of tolerance.
Marie Camacho-Halili, Roxanne George, Malcolm Gottesman, Mark Davis-Lorton

Mult Scler· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863).
Douglas E Gladstone, Robert Peyster, Edward Baron, Sharon Friedman-Urevich, Patrick Sibony, Malcolm Gottesman

Am J Ther· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-beta1b for the treatment of multiple sclerosis.
Sum Lam, Shan Wang, Malcolm Gottesman

Expert Opin Drug Metab Toxicol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carotid artery dissection and stroke caused by airbag injury.
Malcolm Gottesman, Bruce Sanderov, Orlando Ortiz

Am J Emerg Med· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis